Trophoblast cell surface antigen 2 (Trop-2), a transmembrane glycoprotein, is expressed in all subtypes of breast cancer, especially in more than 85% of triple-negative breast cancer (TNBC) [1], where its high expression is associated with a poor prognosis [2,3]. The gene discussed is TACSTD2; the disease is triple-negative breast carcinoma.